Trial · NCT03181503
Results by group242
Each measurement the trial posted, group by group, in the words and numbers it posted.
61 to 80 of 242
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change From Baseline in Weekly Average of the Peak of Pruritus Verbal Rating Scale (VRS) Score at Each Visit Using LOCF Approach | Placebo | Week 1 | -9.8 | Standard Deviation 14.24 | Percent change |
| Percent Change From Baseline in Weekly Average of the Peak of Pruritus Verbal Rating Scale (VRS) Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 1 | -27.6 | Standard Deviation 17.21 | Percent change |
| Percent Change From Baseline in Weekly Average of the Peak of Pruritus Verbal Rating Scale (VRS) Score at Each Visit Using LOCF Approach | Placebo | Week 2 | -12.3 | Standard Deviation 17.64 | Percent change |
| Percent Change From Baseline in Weekly Average of the Peak of Pruritus Verbal Rating Scale (VRS) Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 2 | -39.1 | Standard Deviation 25.38 | Percent change |
| Percent Change From Baseline in Weekly Average of the Peak of Pruritus Verbal Rating Scale (VRS) Score at Each Visit Using LOCF Approach | Placebo | Week 4 | -15.6 | Standard Deviation 20.95 | Percent change |
| Percent Change From Baseline in Weekly Average of the Peak of Pruritus Verbal Rating Scale (VRS) Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 4 | -50.7 | Standard Deviation 29.37 | Percent change |
| Percent Change From Baseline in Weekly Average of the Peak of Pruritus Verbal Rating Scale (VRS) Score at Each Visit Using LOCF Approach | Placebo | Week 8 | -20.7 | Standard Deviation 21.22 | Percent change |
| Percent Change From Baseline in Weekly Average of the Peak of Pruritus Verbal Rating Scale (VRS) Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 8 | -54.3 | Standard Deviation 30.61 | Percent change |
| Percent Change From Baseline in Weekly Average of the Peak of Pruritus Verbal Rating Scale (VRS) Score at Each Visit Using LOCF Approach | Placebo | Week 12 | -19.4 | Standard Deviation 23.60 | Percent change |
| Percent Change From Baseline in Weekly Average of the Peak of Pruritus Verbal Rating Scale (VRS) Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 12 | -56.9 | Standard Deviation 32.64 | Percent change |
| Percent Change From Baseline in Weekly Average of the Peak of Pruritus Verbal Rating Scale (VRS) Score at Each Visit Using LOCF Approach | Placebo | Week 16 | -21.2 | Standard Deviation 22.24 | Percent change |
| Percent Change From Baseline in Weekly Average of the Peak of Pruritus Verbal Rating Scale (VRS) Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 16 | -55.6 | Standard Deviation 34.48 | Percent change |
| Percent Change From Baseline in Weekly Average of the Peak of Pruritus Verbal Rating Scale (VRS) Score at Each Visit Using LOCF Approach | Placebo | Week 18 | -23.0 | Standard Deviation 21.97 | Percent change |
| Percent Change From Baseline in Weekly Average of the Peak of Pruritus Verbal Rating Scale (VRS) Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 18 | -53.4 | Standard Deviation 36.56 | Percent change |
| Absolute Change From Baseline in Weekly Average of the Peak of Pruritus Verbal Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 1 | -0.3 | Standard Deviation 0.47 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Peak of Pruritus Verbal Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 1 | -0.9 | Standard Deviation 0.57 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Peak of Pruritus Verbal Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 2 | -0.4 | Standard Deviation 0.61 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Peak of Pruritus Verbal Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 2 | -1.3 | Standard Deviation 0.83 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Peak of Pruritus Verbal Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 4 | -0.6 | Standard Deviation 0.74 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Peak of Pruritus Verbal Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 4 | -1.6 | Standard Deviation 1.00 | Units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03181503/results?page=4